Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium)

Journal of Clinical Pathology

Volumn 62, Issue 2, 2009, Pages 128-138

  De Jong, D ^a   Xie, W ^b   Rosenwald, A ^c   Chhanabhai, M ^d   Gaulard, P ^e   Klapper, W ^f   Lee, A ^g   Sander, B ^h   Thorns, C ^f   Campo, E ⁱ   Molina, T ^j   Hagenbeek, A ^k   Horning, S ^l   Lister, A ^g   Raemaekers, J ^m   Salles, G ⁿ   Gascoyne, R D ^d   Weller, E ^b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e HENRI MONDOR HOSPITAL   (France)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^h KAROLINSKA INSTITUTE   (Sweden)

ⁱ UNIVERSITY OF BARCELONA   (Spain)

^j UNIVERSITÉ PARIS DESCARTES   (France)

^k ACADEMIC MEDICAL CENTER   (Netherlands)

^l STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^m RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ HOSPICES CIVILS DE LYON   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD20 ANTIGEN; CD5 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; HLA DR ANTIGEN; INTERFERON REGULATORY FACTOR 4; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN BCL 6;

ARTICLE; CONTROLLED STUDY; DISEASE MARKER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSTIMULATION; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; TISSUE MICROARRAY; VALIDATION PROCESS;

EID: 61449156367     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2008.057257     Document Type: Article

References (32)

1. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
2. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Mad 2002;346:1937-47.
3. Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005;105:1851- 61.
4. Feuerhake F, Kutok JL, Monti S, et al. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 2005;106:1392-9.
5. Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002;99:1136-43.
6. Colomo L, Lopez-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003;101:78-84.
7. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-82.
8. Chang CC, McClintock S, Cleveland RP, et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004;28:464-70.
9. de Paepe P, Achten R, Verhoef G, et al. Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathological entities within the group of diffuse large B-cell lymphomas. J Clin Oncol 2005;23:1-9.
10. Berglund M, Thunberg U, Amini R-M, et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol 2005;18:1113-20.
11. Zinzani PL, Dirnhofer S, Sabatini E, et al. Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue microarrays. Haematologica 2005;90:341-7.
12. van Imhoff GW, Boerma EJG, van der Holt B, et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 2006;24:4135-42.
13. Kramer MH, Hermans J, Parker J, et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol 1996;14:2131-8.
14. Hill ME, MacLennan KA, Cunningham DC, et al. Prognostic significance of bcl-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. Blood 1996;88:1046-51.
15. Hermine O, Haioun C, Lepage E, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Blood 1996;87:265-72.
16. Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of bcl-2 protein expression and bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997;90:244-51.
17. Iqbal J, Sanger WG, Horsman DE, et al. Bcl-2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol 2004;165:159-66.
18. Lossos IS, Jones CD, Warnke R, et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 2001;98:945-51.
19. Adida C, Haioun C, Gaulard P, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000;96:1921-5.
20. Sagaert X, de Paepe P, Libbrecht L, et al. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J Clin Oncol 2006;24:2490-7.
21. Banham AH, Connors JM, Brown PJ, et al. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancar Res 2005;11:1065-72.
22. Winter JN, Weller EA, Horning SJ, et al. Prognostic significance of bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study.Blood 2006;107:4207-13.
23. Barrans SL, Fenton JA, Banham A, et al. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 2004;104:2933-5.
24. Kersten MJ, de Jong D, Raemaekers, et al. Beyond the International Prognostic Index: new prognostic factors in follicular lymphoma and diffuse large-cell lymphomaA meeting report of the Second International Lunenburg Lymphoma Workshop. Hamatol J 2004;5:202-8.
25. Woolson RF, Clarke WR. Statistical methods for the analysis of biomedical data. Hoboken, NJ: Wiley, 2002.
26. Efron B, Tibshirani RJ. An introduction to tha bootstrap. London: Chapman & Hall, 1993.
27. Zu Y, Steinberg SM, Campo E, et al. Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphoma. Leuk Lymph 2005;46:693-701.
28. Moskowitz CH, Zelenetz AD, Kwealramani T, et al. Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL. Blood 2005;106:3383- 5.
29. Oschlies I, Klapper W, Zimmerman M, et al. Diffuse large B-cell lymphoma in paediatric patients predominantly belong to the germinal-center type B-cell lymphomas. Blood 2006;107:4047-52.
30. Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006;24:3032-8.
31. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003;101:4279-84.
32. Iqbal J, Neppalli VT, Wright G, et al. Bcl-2 expression is a prognostic marker for activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006;24:961-8.